Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers

microRNA-210 as a prognostic factor in patients with breast cancer: Meta-analysis

(2017) Yanyan Li et al.   Cancer Biomarkers

BRCA1 germline mutation and glioblastoma development: report of cases

(2015) Meriem Boukerroucha et al.   BMC CANCER

BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer

(2015) Elif Erturk et al.   GENE

Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

(2015) Clare L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer

(2015) Nicolas Bovy et al.   Oncotarget

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

(2014) T. Byrski et al.   BREAST CANCER RESEARCH AND TREATMENT

Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression

(2014) Pierre Frères et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The Role of MicroRNAs in the Control of Innate Immune Response in Cancer

(2014) Simon Jasinski-Bergner et al.   JNCI-Journal of the National Cancer Institute

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function

(2014) E Kumaraswamy et al.   ONCOGENE

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

(2013) E H Lips et al.   BRITISH JOURNAL OF CANCER

A rich internet application for remote visualization and collaborative annotation of digital slides in histology and cytology

(2013) Raphaël Marée et al.   Diagnostic Pathology

The shaping and functional consequences of the microRNA landscape in breast cancer

(2013) Heidi Dvinge et al.   NATURE

starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data

(2013) Jun-Hao Li et al.   NUCLEIC ACIDS RESEARCH

Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer

(2013) Luciano Cascione et al.   PLoS One

Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer

(2013) S. Volinia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genome-Wide Analysis of mir-548 Gene Family Reveals Evolutionary and Functional Implications

(2012) Tingming Liang et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex

(2012) Shinji Kawai et al.   JOURNAL OF CELL BIOLOGY

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

(2012) Louise J Barber et al.   JOURNAL OF PATHOLOGY

DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways

(2012) Ioannis S. Vlachos et al.   NUCLEIC ACIDS RESEARCH

microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer

(2011) F. M. Buffa et al.   CANCER RESEARCH

Down-regulation ofBRCA1expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers

(2011) Amandine I. Garcia et al.   EMBO Molecular Medicine

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

(2011) Barbara Norquist et al.   JOURNAL OF CLINICAL ONCOLOGY

Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin

(2010) Igor P. Pogribny et al.   INTERNATIONAL JOURNAL OF CANCER

BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors

(2010) Jurgen Veeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET